Could Orexin-A Reflect Symptom Burden in Allergic Rhinitis?
Allergic rhinitis (AR) can affect more than nasal symptoms as it contributes to disrupted sleep, fatigue, impaired concentration, and reduced social productivity. For patients with persistent symptoms despite medical therapy, nasal surgery can provide relief.
A recent study explored whether these improvements might also be reflected in the neuropeptide, orexin. Orexin is primarily produced in the hypothalamus and helps regulate wakefulness, attention, and vigilance, although orexin-A can also be detected in peripheral blood. The researchers investigated whether circulating orexin could provide an objective measure reflecting the broader symptom burden associated with AR.
Tracking Orexin Before And After Surgery
Researchers evaluated 56 patients with perennial AR undergoing nasal surgery and 7 healthy controls. Patients had persistent symptoms despite treatment with antihistamines, intranasal corticosteroids, and/or oral corticosteroids. Blood samples were collected before surgery and 3 to 6 months afterward, with morning sampling used to minimize diurnal variation.
Symptoms and quality of life (QOL) were assessed using the Japanese Allergic Rhinitis Standard Quality of Life Questionnaire, while serum orexin and several neuroendocrine markers were measured using ELISA.
Orexin Increased as Symptoms Improved
Both nasal symptoms and QOL scores improved significantly following surgery. Before surgery, serum orexin concentrations were significantly lower in patients with AR than in healthy controls. Following surgery, orexin increased to levels that were not significantly different from controls. Paired analyses similarly showed decreasing symptom scores alongside increasing orexin concentrations.
Lower orexin levels were also associated with greater symptom burden. Significant negative correlations were observed with nasal congestion (r=−0.4115, p<0.05), reduced productivity (r=−0.5480, p<0.01), poor concentration (r=−0.5701, p<0.001), reduced thinking ability (r=−0.4228, p<0.05), memory impairment (r=−0.4182, p<0.05), sleep impairment (r=−0.3930, p<0.05), fatigue (r=−0.3828, p<0.05), and overall QOL symptom scores (r=−0.4904, p<0.01).
Other neuroendocrine markers were less closely aligned with clinical symptoms. β-Endorphin did not significantly change, whereas adrenocorticotropic hormone (ACTH) increased and cortisol decreased after surgery.
A Potential Biomarker, But Not Yet a Clinical Measure
The findings suggest that serum orexin may parallel changes in AR symptom burden and QOL, including concentration, productivity, sleep, and fatigue. However, the observational design cannot establish whether improvement in AR directly caused the increase in orexin, and the underlying mechanisms remain unclear. The small control group and uncertainty about whether orexin changes are specific to AR also limit interpretation.
So for now, serum orexin represents a potential biomarker rather than an established measure of treatment response. Further studies, including evaluations after nonsurgical AR treatments, will be needed to determine whether orexin can reliably provide an objective window into symptom and QOL improvement.
Reference:
Maegawa A, Sato Y, Imoto Y, et al. Serum orexin levels reflect quality of life and symptom burden in patients with allergic rhinitis after nasal surgery. Allergol Int. Published online September 21, 2026. doi:10.1016/j.alit.2026.08.007
